Spinogenix Announces Second Grant Award from U.S. Department of Defense to Further Advance SPG302, the First Synaptic Regenerative Drug to Treat Amyotrophic Lateral Sclerosis (ALS)
SPG302 Already in Phase 1 Human Clinical Trials in AustraliaSAN DIEGO, Sept. 26, 2023 (GLOBE NEWSWIRE) -- Spinogenix, Inc., a...
Read moreDetails